Johnson & Johnson
As of Fiscal Year 2025 (ended December 28, 2025)
Key KPIs at a Glance
| Metric | Value |
|---|---|
| Total revenue (FY2025) | $94.19 billion, up 6.0% year-over-year (reported) |
| Net income (FY2025) | $26.80 billion, up about 91% versus $14.07 billion in FY2024 (prior-year figure was depressed by one-time litigation/IPR&D charges; see note above) |
| Adjusted net earnings (FY2025, non-GAAP) | $26.2 billion, up 8.1% year-over-year |
| Diluted EPS (FY2025) | $11.03 reported; $10.79 adjusted (non-GAAP) |
| Innovative Medicine segment revenue (FY2025) | $60.40 billion, up 6.0% reported / 5.3% operational, led by DARZALEX, CARVYKTI, ERLEADA, RYBREVANT/LAZCLUZE and TREMFYA, partly offset by STELARA erosion from biosimilar competition |
| MedTech segment revenue (FY2025) | $33.79 billion, up 6.1% reported / 5.4% operational, led by electrophysiology, Abiomed cardiovascular products and general surgery wound closure |
| Free cash flow (FY2025) | approximately $19.7 billion |
Sources: Revenue, segment, net income and EPS figures are company-disclosed, from J&J's Q4/FY2025 earnings release (reported January 21, 2026). J&J separated its Consumer Health business as the standalone company Kenvue in August 2023; all revenue history shown here (fiscal years 2023-2025) uses J&J's restated continuing-operations figures that exclude Kenvue/Consumer Health, so the trend is on a comparable basis, but earlier (pre-2023) reported revenue is not comparable and is intentionally omitted. Net income of $26.8 billion for FY2025 rose about 91% year-over-year versus FY2024's $14.1 billion; that FY2024 base was depressed by large one-time litigation and IPR&D-related charges, so the FY2025 net income growth rate substantially overstates underlying operating improvement (J&J's own adjusted net earnings, a non-GAAP measure that excludes such items, grew a more modest 8.1% year-over-year to $26.2 billion).